focus -WSS

focus

author：leisure time 2025-10-02 22:27:38 - browse：1221

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： For Cytokinetics, FDA rejection of heart drug would help, not hinder

WSS

Patients' immediate access to test results puts radiologists in a bind

Anavex keeps shifting the goalposts in its clinical trials

In same hospitals, Black patients receive fewer opioids than white patients

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Americans' trust in science, scientist continues decline: Report

Drastic changes should bring profitability, startup health insurers say

hotspot

focus

Wikipedia

Alkermes shareholders re

In diabetes hearing, Sanders takes on a new foe: food makers

Wildfire smoke exposes gaps in outdoor worker protections

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Jerome Adams on the need for new antivirals for Covid

CMS should re

Wildfire smoke exposes gaps in outdoor worker protections

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Psychedelics group wrestles with new pharma identity

In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

What causes an itch? Researchers may have solved the mystery

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

SCOTUS to consider access to abortion pill mifepristone

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

explore

leisure time

explore

Wikipedia